Myxoma virus mutants for cancer treatment
AssigneeRobarts Research Institute
InventorsJOHN W. BARRETT, GRANT MCFADDEN
Life of this patent
Estimating the term…
Abstract
Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
Claims7
1-13. (canceled)
A method for inhibiting a cancer cell comprising administering to the cell an effective amount of a Myxoma virus in which the gene for Myxoma virus protein M11L has been deleted or otherwise knocked-out.
The method of claim 4, wherein the cell is a mammalian cancer cell.
The method of claim 4, wherein the cell is a human cancer cell.
The method of claim 4, wherein the cell is a glioma cell.
A method for treating a human subject having cancer, comprising administering to the subject an effective amount of a Myxoma virus in which the gene for Myxoma virus protein M11L has been deleted or otherwise knocked-out.
Dependencies are inferred from the claim text.